ReviewRheumatology advances in practice2025
Pan American League of Associations for Rheumatology treatment recommendations for systemic juvenile idiopathic arthritis.
Review in Rheumatology advances in practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to develop evidence-based Pan American League of Associations for Rheumatology recommendations for the pharmacological treatment of systemic juvenile idiopathic arthritis (sJIA). An expert panel of paediatric rheumatologists from Latin America generated clinically meaningful research questions structured using the Population, Intervention, Comparator and Outcome (PICO) format, adhering to Grading of Recommendations Assessment, Development, and Evaluation methodology. A team of methodologists conducted a systematic literature review, extracted and summarized intervention effect estimates and graded the evidence quality. The JIA expert panel voted on each research question structured using the PICO format, requiring a minimum agreement of 70% among the voting members to formulate recommendations. Four evidence-based recommendations were developed, addressing the two most common phenotypes of sJIA: with predominantly systemic features and with predominantly active synovitis. The optimal therapeutic approach emphasizes the early initiation of IL-1 or IL-6 pathway inhibition, coupled with a short-course corticosteroid regimen. For sJIA patients with predominantly systemic features and high disease activity, high-dose i.v. methylprednisolone ('pulse therapy') is advised. These recommendations highlight the importance of limiting glucocorticoid therapy to the lowest effective dose for the shortest possible duration, with gradual tapering and discontinuation within a maximum period of 6 months. These recommendations provide guidance on strategies for the use of pharmacological agents for sJIA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.